Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia

International Clinical Psychopharmacology

Volumn 23, Issue 2, 2008, Pages 95-105

  Möller, Hans Jürgen ^a   Johnson, Sunny ^b   Mateva, Temenuzhka ^c   Brecher, Martin ^d   Svensson, Ola ^e   Miller, Frank ^e   Meulien, Didier ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CREDIT VALLEY HOSPITAL   (Canada)

^c District Dispensary for Psychiatric Disorders   (Bulgaria)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Atypical antipsychotic; Extended release quetiapine fumarate; Outpatients; Quetiapine; Schizophrenia; Switching

Indexed keywords

QUETIAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 39849096268     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282f2d42c     Document Type: Article

References (33)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association.
2. Arvanitis LA, Miller BG, the Seroquel Trial 13 study group (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246.
3. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW (2006a). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67:453-460.
4. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR (2006b). A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 67:1114-1123.
5. Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, et al. (2006). A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39:135-141.
6. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
7. Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group (1996). ICI 204 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16:158-169.
8. Buckley PF (2004). Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 20:1357-1363.
9. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360.
10. Claxton AJ, Cramer J, Pierce C (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310.
11. Committee on Proprietary Medicinal Products (1999). Points to Consider on Biostatistical Issues Arising from Recent CPMP Discussions on Licensing Applications: Superiority, Non-inferiority and Equivalence (Draft).
12. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108.
13. Dolder CR, Lacro JP, Jeste DV (2003). Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 65:156-162.
14. Donohoe G, Owens N, O'Donnell C, Burke T, Moore L, Tobin A, et al. (2001). Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 16:293-298.
15. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR (1990). The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881-1884.
16. FDA. Guidance for Industry: Acute Bacterial Sinusitis Developing Antimicrobial Drugs for Treatment. (Draft Guidance.), revised 1998. Available at http://69.20.19.211/cder/guidance/index.htm.
17. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D, Study 147 Investigators. (2008). Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 24:21-32.
18. Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards G, et al. (2006). Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. Br J Psychiatry 188:223-228.
19. Hellewell JSE, Cameron-Hands D, Cantillon M (1998). Seroquel: evidence for efficacy in the treatment of hostility and aggression. Schizophr Res 29:154-155.
20. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. (2007). Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:832-842.
21. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
22. Leucht S, Heres S (2006). Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 (Suppl 5):3-8.
23. Möller HJ, Bottlender R, Gross A, Hoff P, Wittmann J, Wegner U, et al. (2002). The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. Schizophr Res 56:87-94.
24. National Institute of Mental Health (1976). CGI Clinical Global Impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU Assessment Battery 2. Rev Ed. Chevy Chase, Maryland: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. pp. 217-222.
25. National Institutes of Mental Health (1970). CGI: Clinical Global Impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU Assessment Battery. Chevy Chase, Maryland: NIMH. pp. 1-6.
26. Newcombe RG (1998). Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17:873-890.
27. Palmer BA, Pankratz VS, Bostwick JM (2005). The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62:247-253.
28. Peuskens J, Trivedi JK, Malyarov S, Brecher M, Svensson O, Miller F, et al. (2007). Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a ramdomized placebo-controlled trial in clinically stable patients. Psychiatry 4:34-50.
29. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG (2003). Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64:1048-1056.
30. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
31. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, the Seroquel Study Group (1997). Quetiapine in patients with schizophrenia. A highand low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54:549-557.
32. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600-609.
33. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M (2005). Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 21:923-934.